Table 1.
Baseline characteristics of the trial population
| All participants | Male | Female | ||||
|---|---|---|---|---|---|---|
| Characteristic | N | N = 19,114 | N | N = 8,332 | N | N = 10,782 |
| Age (years) | 19,114 | 74.0 (71.6, 77.7) | 8,332 | 73.8 (71.6, 77.3) | 10,782 | 74.1 (71.7, 77.9) |
| Ethnicity/race | 19,114 | 8,332 | 10,782 | |||
| White | 17,450 (91.3%) | 7,681 (92.2%) | 9,769 (90.6%) | |||
| Black | 901 (4.7%) | 307 (3.7%) | 594 (5.5%) | |||
| Hispanic | 488 (2.6%) | 202 (2.4%) | 286 (2.7%) | |||
| Others | 275 (1.4%) | 142 (1.7%) | 133 (1.2%) | |||
| Country | 19,114 | 8,332 | 10,782 | |||
| Australia | 16,703 (87.4%) | 7,524 (90.3%) | 9,179 (85.1%) | |||
| US | 2,411 (12.6%) | 808 (9.7%) | 1,603 (14.9%) | |||
| Living status | 19,114 | 8,332 | 10,782 | |||
| At home alone | 6,251 (32.7%) | 1,729 (20.8%) | 4,522 (41.9%) | |||
| At home with family, friends or spouse | 12,863 (67.3%) | 6,603 (79.2%) | 6,260 (58.1%) | |||
| Years of education | 19,113 | 8,332 | 10,781 | |||
| < 9 | 3,002 (15.7%) | 1,347 (16.2%) | 1,655 (15.4%) | |||
| 9–11 | 5,634 (29.5%) | 2,306 (27.7%) | 3,328 (30.9%) | |||
| 12 | 2,319 (12.1%) | 947 (11.4%) | 1,372 (12.7%) | |||
| 13–15 | 3,255 (17.0%) | 1,344 (16.1%) | 1,911 (17.7%) | |||
| 16 | 1,766 (9.2%) | 734 (8.8%) | 1,032 (9.6%) | |||
| 17–21 | 3,137 (16.4%) | 1,654 (19.9%) | 1,483 (13.8%) | |||
| Type 2 diabetes | 19,114 | 2,045 (10.7%) | 8,332 | 1,046 (12.6%) | 10,782 | 999 (9.3%) |
| Smoking history | 19,114 | 8,332 | 10,782 | |||
| Current | 735 (3.8%) | 383 (4.6%) | 352 (3.3%) | |||
| Former/never | 18,379 (96.2%) | 7,949 (95.4%) | 10,430 (96.7%) | |||
| Alcohol consumption | 19,114 | 8,332 | 10,782 | |||
| Current | 14,642 (76.6%) | 6,932 (83.2%) | 7,710 (71.5%) | |||
| Former/never | 4,472 (23.4%) | 1,400 (16.8%) | 3,072 (28.5%) | |||
| Family history of myocardial infarction | 17,605 | 497 (2.8%) | 7,674 | 180 (2.3%) | 9,931 | 317 (3.2%) |
| History of cancer | 19,035 | 3,660 (19.2%) | 8,294 | 1,790 (21.6%) | 10,741 | 1,870 (17.4%) |
| Non-HDL-c (mmol/L) | 18,666 | 3.60 (3.00, 4.30) | 8,125 | 3.60 (3.00, 4.20) | 10,541 | 3.60 (3.00, 4.30) |
| HDL-c (mmol/L) | 18,668 | 1.50 (1.30, 1.80) | 8,126 | 1.30 (1.10, 1.60) | 10,542 | 1.70 (1.40, 2.00) |
| eGFR (mL/min per 1.73 m2) | 18,650 | 74 (63, 84) | 8,114 | 74 (64, 84) | 10,536 | 74 (63, 85) |
| Haemoglobin (g/dL) | 19,112 | 14.10 (13.30, 15.00) | 8,330 | 14.90 (14.10, 15.60) | 10,782 | 13.60 (13.00, 14.30) |
| Systolic blood pressure (mmHg) | 19,114 | 139 (127, 151) | 8,332 | 141 (130, 152) | 10,782 | 137 (125, 149) |
| Diastolic blood pressure (mmHg) | 19,114 | 77 (70, 84) | 8,332 | 78 (72, 85) | 10,782 | 76 (69, 84) |
| Body mass index (kg/m2) | 19,025 | 27.5 (24.9, 30.7) | 8,300 | 27.6 (25.3, 30.1) | 10,725 | 27.5 (24.5, 31.2) |
| Waist circumference (cm) | 18,905 | 97 (89, 105) | 8,269 | 101 (95, 108) | 10,636 | 93 (84, 102) |
| Grip strength (kg) | 18,828 | 25 (20, 34) | 8,231 | 35 (30, 40) | 10,597 | 20.7 (17.0, 24.3) |
| Gait speed (m/s) | 19,018 | 1.01 (0.87, 1.15) | 8,295 | 1.04 (0.91, 1.19) | 10,723 | 0.99 (0.84, 1.13) |
| Lipid-lowering agents | 19,114 | 5,987 (31.3%) | 8,332 | 2,337 (28.0%) | 10,782 | 3,650 (33.9%) |
| Antihypertensive agents | 19,114 | 10,062 (52.6%) | 8,332 | 4,089 (49.1%) | 10,782 | 5,973 (55.4%) |
| Treatment randomization | 19,114 | 8,332 | 10,782 | |||
| Placebo | 9,589 (50.2%) | 4,180 (50.2%) | 5,409 (50.2%) | |||
| Aspirin | 9,525 (49.8%) | 4,152 (49.8%) | 5,373 (49.8%) | |||
| 3MS | 19,114 | 94 (91, 97) | 8,332 | 94 (90, 96) | 10,782 | 95 (92, 97) |
| CES-D (≥8) | 19,110 | 1,879 (9.8%) | 8,331 | 631 (7.6%) | 10,779 | 1,248 (11.6%) |
The numbers are presented as median with interquartile range or as absolute and relative numbers. Abbreviations: N number of participants with available data, HDL-c high-density lipoprotein cholesterol, 3MS Modified Mini-Mental State, CES-D Centre for Epidemiologic Studies-Depression 10 question assessment